TWI813566B - 醫藥組成物 - Google Patents

醫藥組成物 Download PDF

Info

Publication number
TWI813566B
TWI813566B TW107113537A TW107113537A TWI813566B TW I813566 B TWI813566 B TW I813566B TW 107113537 A TW107113537 A TW 107113537A TW 107113537 A TW107113537 A TW 107113537A TW I813566 B TWI813566 B TW I813566B
Authority
TW
Taiwan
Prior art keywords
patent application
item
oxo
fluoro
hydroxyethyl
Prior art date
Application number
TW107113537A
Other languages
English (en)
Chinese (zh)
Other versions
TW201842912A (zh
Inventor
麥可 李德
尼可拉 伊莉莎白 威施爾
馬可 亨利 桑德爾斯
保羅 安東尼 巴格利
柯林 湯瑪斯 林得利
羅伯特 桂格 美林
寶茲納 艾娃 阿達姆斯柯
莫爾卡 斯卡拉提
Original Assignee
日商大塚製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大塚製藥股份有限公司 filed Critical 日商大塚製藥股份有限公司
Publication of TW201842912A publication Critical patent/TW201842912A/zh
Application granted granted Critical
Publication of TWI813566B publication Critical patent/TWI813566B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW107113537A 2017-04-20 2018-04-20 醫藥組成物 TWI813566B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1706327.2 2017-04-20
??1706327.2 2017-04-20
GBGB1706327.2A GB201706327D0 (en) 2017-04-20 2017-04-20 A pharmaceutical compound

Publications (2)

Publication Number Publication Date
TW201842912A TW201842912A (zh) 2018-12-16
TWI813566B true TWI813566B (zh) 2023-09-01

Family

ID=58795788

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107113537A TWI813566B (zh) 2017-04-20 2018-04-20 醫藥組成物

Country Status (21)

Country Link
US (3) US11142518B2 (https=)
EP (1) EP3612524B1 (https=)
JP (1) JP7113846B2 (https=)
KR (1) KR102652193B1 (https=)
CN (1) CN110831939B (https=)
AU (1) AU2018255935B2 (https=)
CA (1) CA3059674A1 (https=)
DK (1) DK3612524T3 (https=)
ES (1) ES2994283T3 (https=)
FI (1) FI3612524T3 (https=)
GB (1) GB201706327D0 (https=)
IL (1) IL269803B (https=)
MA (1) MA52123A (https=)
MX (1) MX2019012471A (https=)
MY (1) MY203722A (https=)
PH (1) PH12019502154A1 (https=)
SA (1) SA519410253B1 (https=)
SG (1) SG11201909189QA (https=)
TW (1) TWI813566B (https=)
WO (1) WO2018193410A1 (https=)
ZA (1) ZA201907484B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE068392T2 (hu) * 2015-10-21 2024-12-28 Otsuka Pharma Co Ltd Benzolaktám vegyületek mint fehérje kináz gátlók
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
IL276232B2 (en) 2018-03-02 2024-04-01 Otsuka Pharma Co Ltd Pyrazine derivatives, pharmaceutical compositions comprising them and their use for treating diseases
MX2021000795A (es) 2018-07-24 2021-04-12 Taiho Pharmaceutical Co Ltd Compuestos heterociclicos para inhibir la actividad de shp2.
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
TW202140024A (zh) * 2020-01-24 2021-11-01 日商大鵬藥品工業股份有限公司 Shp2抑制劑嘧啶酮與新穎癌症醫藥併用於癌症之抗腫瘤活性之增強
CN115443274B (zh) * 2020-04-30 2025-04-25 勤浩医药（苏州）有限公司 含苯基并内磺酰胺的化合物
CN113967198A (zh) * 2020-07-24 2022-01-25 鲁南制药集团股份有限公司 一种甾体cyp17抑制剂胶囊及其制备方法
US20230312564A1 (en) * 2020-08-21 2023-10-05 Shanghai Ringene Biopharma Co., Ltd. Aromatic ring-lactam compound, preparation method therefor and use thereof
KR20240021198A (ko) * 2021-06-11 2024-02-16 오츠카 세이야쿠 가부시키가이샤 Erk 억제제의 제조 방법
US11931370B2 (en) * 2021-10-08 2024-03-19 Slayback Pharma Llc Stable pharmaceutical compositions of cyclophosphamide
US20240415835A1 (en) * 2021-10-26 2024-12-19 Otsuka Pharmaceutical Co., Ltd. Compositions comprising an erk inhibitor
CN114085213B (zh) * 2022-01-20 2022-03-25 苏州国匡医药科技有限公司 一种arv-471的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016025649A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a dot1l inhibitor and related methods
TW201613865A (en) * 2014-01-14 2016-04-16 Millennium Pharm Inc Heteroaryls and uses thereof
TW201722933A (zh) * 2015-10-21 2017-07-01 大塚製藥股份有限公司 苯內醯胺化合物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5958934A (en) 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
JP2003504301A (ja) 1998-04-01 2003-02-04 ブリストル−マイヤーズ スクイブ ファーマ カンパニー インテグリンアンタゴニスト
CA2450934A1 (en) 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
MXPA05011523A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas.
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
UA84930C2 (ru) 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
WO2006113769A1 (en) 2005-04-15 2006-10-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
KR101417136B1 (ko) 2005-12-13 2014-08-07 머크 샤프 앤드 돔 코포레이션 Ｅｒｋ 억제제인 폴리사이클릭 인다졸 유도체 및 이를 포함하는 약제학적 조성물
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
CA2654670A1 (en) 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh New compounds
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
WO2009039635A1 (en) 2007-09-24 2009-04-02 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
EP2215074B1 (en) 2007-09-27 2014-02-19 The United States of America, as Represented by the Secretary, Department of Health and Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009092432A1 (en) 2008-01-24 2009-07-30 Merck Patent Gmbh Beta-amino acid derivatives for treatment of diabetes
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
US8084620B2 (en) 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
EP2429987A4 (en) 2009-05-15 2012-10-03 Korea Res Inst Chem Tech AMIDE COMPOUND, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
WO2010151747A1 (en) 2009-06-26 2010-12-29 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimine compounds and methods of making and using same
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
KR101758046B1 (ko) 2009-12-22 2017-07-14 버텍스 파마슈티칼스 인코포레이티드 포스파티딜이노시톨 3-키나제의 이소인돌리논 억제제
AU2010336027A1 (en) 2009-12-23 2012-07-19 Auckland Uniservices Limited Compounds, preparations and uses thereof
NZ601526A (en) 2009-12-31 2014-07-25 Piramal Entpr Ltd Inhibitors of diacylglycerol acyl transferase
WO2012002527A1 (ja) 2010-07-02 2012-01-05 あすか製薬株式会社 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤
PE20130774A1 (es) 2010-07-29 2013-06-26 Rigel Pharmaceuticals Inc Compuestos heterociclicos activadores de ampk y metodos para emplearlos
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
DK2820009T3 (en) 2012-03-01 2018-04-16 Array Biopharma Inc Serine / threonine kinase inhibitors
CN104583195B (zh) 2012-09-12 2018-08-17 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
US20150272939A1 (en) 2012-10-02 2015-10-01 Yale University Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
US20140357636A1 (en) 2013-02-21 2014-12-04 Wayne Rothbaum Treatment of Skeletal-Related Disorders
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
CN110229142A (zh) 2014-04-04 2019-09-13 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
WO2015157556A1 (en) 2014-04-09 2015-10-15 Kadmon Corporation, Llc Treatment of gvhd
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
WO2016162325A1 (en) 2015-04-07 2016-10-13 Astrazeneca Ab Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors
BR112017026159A2 (pt) 2015-06-15 2018-08-14 Asana Biosciences, Llc inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
LT3374359T (lt) 2015-11-09 2020-03-25 Astrazeneca Ab Dihidroimidazopirazinono deriniai, tinkami panaudoti vėžio gydymui
EP3492462B1 (en) 2016-07-26 2023-08-30 Shenzhen TargetRx, Inc. Amino pyrimidine compound for inhibiting protein tyrosine kinase activity
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613865A (en) * 2014-01-14 2016-04-16 Millennium Pharm Inc Heteroaryls and uses thereof
WO2016025649A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a dot1l inhibitor and related methods
TW201722933A (zh) * 2015-10-21 2017-07-01 大塚製藥股份有限公司 苯內醯胺化合物

Also Published As

Publication number Publication date
RU2019135029A (ru) 2021-05-20
ZA201907484B (en) 2024-05-30
US20210101889A1 (en) 2021-04-08
MX2019012471A (es) 2019-12-11
FI3612524T3 (fi) 2024-09-24
BR112019019948A2 (pt) 2020-04-28
CA3059674A1 (en) 2018-10-25
TW201842912A (zh) 2018-12-16
KR102652193B1 (ko) 2024-03-29
EP3612524B1 (en) 2024-08-28
ES2994283T3 (en) 2025-01-21
IL269803B (en) 2022-09-01
WO2018193410A1 (en) 2018-10-25
MY203722A (en) 2024-07-16
RU2019135029A3 (https=) 2021-07-16
DK3612524T3 (da) 2024-09-30
IL269803A (en) 2019-11-28
JP7113846B2 (ja) 2022-08-05
US20220169638A1 (en) 2022-06-02
PH12019502154A1 (en) 2020-06-29
CN110831939A (zh) 2020-02-21
KR20190140957A (ko) 2019-12-20
MA52123A (fr) 2020-02-26
US20250002481A1 (en) 2025-01-02
CN110831939B (zh) 2025-05-09
JP2020517598A (ja) 2020-06-18
AU2018255935B2 (en) 2022-03-17
GB201706327D0 (en) 2017-06-07
SA519410253B1 (ar) 2023-07-12
US12030873B2 (en) 2024-07-09
US11142518B2 (en) 2021-10-12
AU2018255935A1 (en) 2019-11-07
SG11201909189QA (en) 2019-10-30
NZ758411A (en) 2024-10-25
EP3612524A1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
TWI813566B (zh) 醫藥組成物
US11939321B2 (en) Benzolactam compounds as protein kinase inhibitors
JP6796588B2 (ja) Ｎ−（３，５−ジメトキシフェニル）−ｎ’−（１−メチルエチル）−ｎ−［３−（１−メチル−１ｈ−ピラゾール−４−イル）キノキサリン−６−イル］エタン−１，２−ジアミンを含んでなる医薬組成物
US12077526B2 (en) Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them
BR122022015241B1 (pt) Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
BR112018005932B1 (pt) Compostos inibidores de isoindolinona, seus processos de preparação, usos, combinações e composições farmacêuticas
JP2022548568A (ja) Ｃｄｋ阻害剤及び医薬品としてのそれらの使用
RS66620B1 (sr) Heterociklična jedinjenja za upotrebu u lečenju kancera
CN116113406B (zh) Gas41抑制剂及其使用方法
CN110603251A (zh) 异吲哚啉酮衍生物和sgi-110的组合
TW202136188A (zh) 金屬鹽及其用途
RU2786994C2 (ru) Фармацевтическое соединение
BR112019019948B1 (pt) Forma cristalina de derivado de 6-pirimidina-isoindol, seu processo de produção, sal amorfo, composição farmacêutica, e seus usos para fabricação de um medicamento
HK40023945A (en) 6-pyrimidin-isoindole derivative as erk1/2 inhibitor
HK40023945B (en) 6-pyrimidin-isoindole derivative as erk1/2 inhibitor
WO2026075274A1 (en) Indazol derivatives useful for treating cancer
HK1256820B (en) Benzolactam compounds as protein kinase inhibitors